I have no financial interests to disclose.
|
|
- Blake Maximillian Harper
- 6 years ago
- Views:
Transcription
1 Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests to disclose. Case Based Problems Emphasis on 2012 guidelines by ASCCP (American Society of Colposcopy and Cervical Pathology) and how they differ from last Changes for <25yos Who needs colposcopy vs who can be managed expectantly? Next steps after colposcopy Treatment options: cryotherapy, laser, LEEP and cone biopsy Post-treatment surveillance Recommended Guidelines ASCCP guidelines 2012 For work-up of abnormal cytology and treatment of CIN: (or just search ASCCP guidelines) Algorithms%204%2011%2013%20-%20PDF.pdf Rationale behind guidelines: ObstetGynecol: 2013; 121(4); SFGH 2010 guidelines in your syllabus (developed by Dr. George Sawaya, very similar to ASCCP but not yet updated with the new 2013 recommendations) 1
2 $7.00 Laminated cards with tabs at top so can find the algorithm you need $9.99 $9.99 Either enter pt info and it gives you the recommendation and assoc algorithm OR you can simply view the algorithms Good news: most prior guidelines reaffirmed, easier to read, guidance for no ECC s on pap & discordant co-test results Bad news: even more complex than prior guidelines What s New (2012 ASCCP) **Extend adolescent (age <21) management guidelines to women < age 25: there are now 2 pathways for most algorithms One for<25 and one for >25 Less aggressive w/u of ASC-US How to manage discordant cotest results: (HPV+/PapNl; HPV-/Pap ASC-US), unsatisfactory cytology and missing endocervical or t- zone cells Post-colpo management now includes co-testing, even in <25 yo Treat CIN1 on ECC as CIN1 (not as +ECC) Histology Primer Cervical intraepithelial neoplasia (CIN) Graded based on proportion of epithelium involved CIN 1: indicates active HPV infection; treatment discouraged since spontaneous resolution is high CIN 2: most are treated, but about 40% resolve over 6 month period; treatment may be deferred in young women CIN 3: the most proximal cancer precursor, also known as carcinoma in situ always treat Adenocarcinoma in situ (AIS): widely considered a cancer precursor always treat 2
3 CIN 1 CIN 3 Case List Case 0 0. Pap normal, HPV positive 1. ASC-US, not young 2. 19yo ASC-H; CIN2 on colpo 3. 78yo ASC-USx2, CIN1 on colpo 4. AGC 5. 22yo ASC-US/HPV+, colpo neg 6. 24yo CIN3 on colpo 7. 58yo CIN3, can t r/o invasion 8. 27yo positive endocervical LEEP margins CIN yo pregnant, HSIL A 35 yo woman has co-test result: HR-HPV positive, cytology normal. What are next steps? 3
4 Pap normal, HPV positive Remember: Use co-test only in women >30yo (b/c HPV often + in younger women and is transient) 2 options: 1. Repeat co-test at 12 months. If both negative 3yr co-test If still HPV+ or if >=AS-CUS colposcopy. 2. HPV genotype-specific typing for 16 & 18 If positive for either colposcopy. If negative repeat co-test at 12 months. Case 1 A 32 year old woman s Pap smear comes back AS-CUS What are your management options? Case 1: AS-CUS, not adolescent Repeat cyto at 1 yr (not 6 mos) OR HPV test. If Neg cotest at 3 yrs 3 equivalent 2 options (HPV preferred): 1. Repeat cytology at 6, 12 months Colpo if >ASC; (if neg cyto in 3 yrs) 2. Immediate colpo 3. Reflex HPV test (preferred) If neg rescreen in 12 months with cytology. Cotest at 3 yrs If pos colposcopy * 2012 guidelines: Less aggressive w/u of AS-CUS 4
5 Case 2 A 19 year old Go woman, sexually active since the age of 15, has a Pap smear read as ASC-H. What are your management options? Although you wish she hadn t had the pap given <21, you can t ignore it ASC-H requires colpo in adults and adolescents. HPV not helpful for triage all get colpo. Management after colpo differs greatly for <25yo Case 2--continued Colposcopy is satisfactory and biopsy-proven CIN 2 is diagnosed in a single quadrant. What are your management options? Be sure to read the fine print lots of info there Work-up and treatment differs for <25 yo (longer surveillance prior to treatment, less aggressive treatment options) Regression is common in younger women and usually occurs within 2 yrs Note now recommend co-test for f/u (even though it breaks the rule of no HPV co-test in <30yo) 5
6 Case 2: CIN 2/3 in adolescents Treatment (excision or ablation) OR observation For CIN2 observation is preferred (as long as colpo is satisfactory*) and patient is reliable (If CIN3 excision/ablation) Colposcopy plus cytology q 6 months for 1 yr If normal cytology x2 co-test 1 yr later, if nl, co-test q 3yr If colpo worsens or high grade cytology or colpo lesion persists x 1yr repeat biopsy Treat only if CIN2 persists for >2 yrs * If colpo unsatisfactory, diagnostic excisional procedure preferred Case 3 A 78 year old woman who has never had any abnormal Pap smears now has a Pap smear read as ASC-US. She has not been sexually active for over 15 years. A repeat pap in 12 months is also ASC-US. Options? Case 3: continued Again, you wish she hadn t had a pap (stop age= 65 in women with prior normals). However, can t ignore.. Two consecutive paps with ASC-US colpo No difference in management of ASCUS for post-menopausal women. However, reflex HPV testing is more efficient than in younger women b/c fewer women will be referred to colposcopy Colposcopy reveals an attenuated, flush cervix. Unsatisfactory. ECC shows CIN 1. Management options? 6
7 Case 4 A 43 year old woman has a Pap smear read as AGC (atypical glandular cells)-not otherwise specified (NOS). Observation ok for CIN1 preceded by ASC-US, LSIL, HPV +. Only treat if persists for 2 years. HPV testing may help to avoid colpo if negative. What is the differential diagnosis of AGC? What are your management options? Differential diagnosis of AGC Atypical endocervical cells Adenocarcinoma-in-situ Adenocarcinoma Squamous CIN Endometrial hyperplasia Endometrial adenocarcinoma Ovarian carcinoma AGC needs more thorough work-up than ASC-US because underlying abnormalities are more serious and more common (40% have SIL, AIS, endometrial hyperplasia) Colpo plus ECC plus EMB (in many) 7
8 Case 4 continued Pt reports occasionally irregular periods. Colposcopy is satisfactory without lesions. ECC is normal. EMB is normal. Note that if initial cytology had been AGC-favor neoplasia and colpo had been negative, cone recommended as next step Given it it AGC-NOS, you follow as per guidelines with co-test at 12 and 24 months 24 month pap is AGC again. Now what? Case 5 An 22year old transfers care to your practice. 8 months ago, she had ASC-US with HPV DNA test positive for a high-risk type. She then had colposcopy at other practice, 6 mos ago, which was noted to be satisfactory with no lesions seen. Repeat AGC: pelvic ultrasound to evaluate ovaries/tubes. If ultrasound negative, cone biopsy Next steps? 8
9 Cytology preferred for f/u AS-CUS in young women (reflex HPV testing ok) If HPV pos repeat cytology only at 12 mos (ie shouldn t have had colpo) What to do when pts receive testing that was not recommended per guidelines or who are lost to f/u after abn pap and then have repeat pap nl? In general, act on most severe abnormality. EG, If 30yo had LSIL pap then lost to f/u and has repeat nl pap, still needs colpo In this case, can follow per guidelines after nl colpo b/c f/u is essentially the same as if she hadn t had colpo Case 6 A 24 yo G0 woman has biopsy-proven CIN 3, a satisfactory colposcopy and a negative endocervical curettage. What are your management options? What if the ECC were positive? Potential adverse effects of LEEP Preterm delivery Low birth weight PPROM Perinatal mortality Severe preterm delivery Extreme low birthweight No randomized trials. 70% 82% 169% Potential adverse effects of cone biopsy Lancet : % 178% 186% BMJ 2008 Sep 18;337 9
10 Case 7 A 58 year old widow has a Pap smear read as ASC-US and you send a test for HPV. It is positive. Given ablative and excisional methods are equally efficacious, choose ablation for women desiring fertility (as long as colpo satisfactory, ECC negative and lesion <2cm and completely visible) Colposcopy is unsatisfactory. ECC shows severe dysplasia (CIN 3) cannot rule out invasion. What are your management options? Case 7: CIN3, can t r/o invasion Typically, CIN3 is treated with LEEP However, if can t r/o invasion, cone biopsy is indicated in order to get a pathologic specimen from which depth of invasion can be assessed Case 8 A 29 yo with biopsy proven CIN3 had a LEEP showing CIN3 with positive endocervical margins. What are the management options? 10
11 Positive LEEP margins If CIN2,3 is identified at the margins of an excisional procedure or post-procedure ECC, cytology and ECC at 4-6mo is preferred, but repeat excision is acceptable and hysterectomy is acceptable if reexcision is not feasible. 5 fold higher rate of recurrence compared to complete excision High grade dz post-treatment in 18% (82% didn t develop it) vs 3% with complete excision Ghaem-Maghami, Lancet-Oncol, 2007 Endocervical vs Ectocervical margins: ASCCP doesn t differentiate. In our practice, we do ECC plus colpo in 6 mos for positive endocervical margins, colpo only for + ectocervical margins Repeat Excision acceptable? Given 82% do not have persistent high grade dz, we advise f/u Case 9 A 16 year old is pregnant within six months of becoming sexually active. She was late to care at 22 weeks at which time she had a Pap smear that was read as HSIL. What are your management options? Case 9: pregnant, hsil Although you wish she d never gotten the pap, now you must act on the HSIL In pregnancy, colpo should be done by experienced colposcopist b/c biopsy will only be done if lesion appears to be invasive cancer. 11
12 General rules Less is better for adolescents/<25yo (start screening later, space out surveillence, less aggressive treatment) Don t use HPV test in <30yo unless it is to follow colpo (possibly can decrease need for repeat colpo, if negative) AGC is worse than ASC-US. Requires extensive work-up Typically don t need to treat CIN1 unless persists Consider getting pap/path results re-read if discordant Pearls Make sure women have adequate education about HPV if HPV DNA testing is used Involve women in decisions when uncertainty exists in guidelines Stress smoking cessation Consider HIV testing for women with biopsy proven dysplasia Final Thoughts Cervical cancer screening will never completely eliminate cervical cancer: must balance benefits (which occur rarely) and harms (which affect a large number of women) Goal: optimal strategies aim to identify HPV-related abnormalities that are likely to progress to invasive cancers while avoiding treating lesions not destined to become cancerous Additional summary from 2012 ASCCP guidelines 12
13 Unsatisfactory or Absent endocervical cells Unsatisfactory cytology: No HPV done or Neg HPV: repeat cytology 2-4 mos Pos HPV: either repeat cyto 2-4 mos or colpo 2 conseq unsats: colpo Cytology Neg but absent/insuff EC/TZ: <30yo: Routine screening (don t do HPV) >30yo, no HPV: Do HPV (pap 3 yr also ok) >30, HPV neg: routine screening > 30 HPV pos: co-test in one year Excision vs ablation Excision: CIN2+ AND unsatisfactory colpo ECC showing CIN2+ Recurrent cin2+ Negative colpo preceded by AIS, AGC-favor neoplasia, HSIL papx2 Ablation: Preferred in younger women (possibly less chance of preterm delivery) Lesion < 2 cm and completely visible 13
14 Guidelines for Screening for Cervical Cancer and its Precursors, 2010 San Francisco General Hospital These are guidelines for use of cervical cytology in asymptomatic women as a screening tool for cervical cancer and its precursors. Tests performed in symptomatic women should be evaluated in clinical context. Screening guidelines do not apply to women with prior treatment of high-grade cervical dysplasia (CIN 2 or CIN 3) or cervical cancer; see other aspects of this guideline for surveillance after treatment. Age to begin screening Age 21 years; avoid screening within 3 years of becoming sexually active and in known virgins. Interval of screening Screen every 2 years with cytology. At or after age 30 years, women with 3+ prior consecutive, normal tests may be screened every 3 years. Age to end screening Screening may end at or after age 65 years if 3+ consecutive, normal cytology tests have been documented within the prior 10 years and there is no history of treated CIN 2, CIN 3, AIS or cervical cancer. Special populations Pregnant women Women with HIV infection or immunocompromised After total hysterectomy in women with no prior history of CIN 2 or CIN 3 After total hysterectomy in women with a prior history of CIN 2 or CIN 3 After diagnosis and treatment of cervical cancer CIN indicates cervical intraepithelial lesion. Screen as above; do not screen within 3 years of becoming sexually active. Annual screening after 2 normal cytology tests 6 months apart in the year following initial HIV diagnosis or immunocompromised state. Screening should not be performed. Annual cytology. After 3 consecutive, normal tests, screening may be performed every 3 years. Surveillance as per gynecologic oncology protocols 1- Sawaya & Smith-McCune, August 2010
15 Guidelines for Initial Management of Abnormal Cervical Cytology, 2010 San Francisco General Hospital Cytology Interpretation Common Benign Findings Unsatisfactory Satisfactory, but no endocervical cells Benign-appearing endometrial cells Epithelial Cell Abnormalities Atypical squamous cells of undetermined significance (ASC-US) ASC, cannot exclude HSIL (ASC-H) Low-grade SIL (LSIL) Action Repeat cytology next available Repeat cytology in 12 months Pre-menopausal: No action. Post-menopausal: Endometrial biopsy. Three different strategies may be adopted, but colposcopy is the least preferred: 1. Repeat cytology at 6 and 12 months. If ASC-US+, colposcopy. After 2 normal cytology tests, resume routine screening. 2. HPV testing for high-risk types. If positive, colposcopy. If negative, repeat cytology in one year; do not do HPV testing in women age 20 or less. 3. Colposcopy If age 20 or less, repeat cytology at 12 months (colposcopy if ASC-H or HSIL+) and at 24 months (colposcopy if ASC-US+). If normal, resume routine screening. For pregnant women age 21+, repeat cytology at 6 months; if ASC-US+, colposcopy 6 weeks post-partum. Colposcopy Colposcopy If age 20 or less, repeat cytology at 12 months (colposcopy if ASC-H or HSIL+) and at 24 months (colposcopy if ASC-US+). If normal, resume routine screening. For pregnant women age 21+, colposcopy may be deferred to 6 weeks postpartum. For post-menopausal women, LSIL may be managed identically to ASC-US. Colposcopy Colposcopy High-grade SIL (HSIL) Squamous cell carcinoma Glandular Cell Abnormalities Atypical glandular cells (AGC) endocervical Colposcopy with endocervical curettage (ECC) endometrial Colposcopy with ECC and EMB not otherwise specified Colposcopy with ECC; add EMB if abnormal bleeding, chronic anovulation or age 35+ Adenocarcinoma in situ (AIS) Common Infections shift in flora suggestive of bacterial vaginosis (BV) Colposcopy with ECC and EMB Consider evaluation of and treatment for BV if symptomatic. Repeat cytology at appropriate screening interval. Consider evaluation of and treatment for yeast vaginitis if symptomatic. Repeat cytology at appropriate screening interval. Diagnostic of HSV. Finding may indicate other STIs. Repeat cytology at appropriate screening interval. fungal organisms consistent with Candida. cellular changes consistent with herpes simplex virus (HSV) Trichomonas vaginalis (TV) Consider evaluation of and treatment for TV if symptomatic. Finding may indicate other STIs. Repeat cytology at appropriate screening interval. DEP indicates diagnostic excisional procedure (e.g., cone biopsy, loop excision). HSIL+ indicates HSIL, AGC, AIS and/or cancer. ASC-US + indicates ASC-US, ASC-H, LSIL and/or HSIL+. ECC indicates endocervical curettage. ECC should be performed in all non-pregnant women with unsatisfactory colposcopy and in those with cytology interpreted as AGC, AIS and cancer. Vaginal colposcopy with Lugol s solution should be performed in all women with no obvious lesion seen and cytology interpreted as HSIL, AGC, AIS or cancer. In pregnant women, ECC is contraindicated. 2- Sawaya & Smith-McCune, August 2010
16 Guidelines for Follow-up after Initial Colposcopy, 2010 San Francisco General Hospital These are guidelines for the most common clinical scenarios. Patients may be managed individually based on clinical judgment. Referral Cytology Findings at initial colposcopy (pre-colposcopy) No visible lesion Visible lesion, biopsy-proven Biopsy-proven ASC-US once ASC-US twice (unknown HPV status) ASC-US, positive high-risk HPV Atypical squamous cells, cannot exclude HSIL (ASC-H) Low- grade SIL (LSIL) CIN 1 Cytology in 12 months. If normal, resume routine screening; if ASC+, repeat colposcopy at the next available appointment. Cytology in 6 and 12 months. The 6-month cytology result should be managed as follows: If ASC or LSIL, repeat colposcopy at the next scheduled appointment (6 months). If ASC-H or HSIL+, repeat colposcopy at the next available appointment. If normal, repeat cytology at the next scheduled appointment (6 months); if cytology is normal at that time (i.e., at the 12-month visit), resume routine screening; if ASC+, repeat colposcopy at the next available appointment. CIN 2 or 3 See Guidelines for Treatment of biopsyproven cervical intraepithelial neoplasia (CIN) 2 (moderate dysplasia) and CIN 3 (CIS, severe dysplasia) High-grade SIL (HSIL) If colposcopy is satisfactory, ECC is normal and the vagina has no lesions, colposcopy and cytology every 6 months for 1 year is acceptable. DEP may also be performed (non-pregnant women only); review of outside cytology suggested prior to DEP. Treatment is preferred. If colposcopy is unsatisfactory, DEP is preferred (non-pregnant women only). Atypical glandular cells (AGC) Cytology in 6, 12, 18 and 24 months. Repeat colposcopy if ASC-US+. After 4 normal cytology tests, resume routine screening. If AGC recurs, perform cone biopsy. Pelvic sonogram to rule out adnexal malignancy is recommended in women with persistent AGC. Adenocarcinoma in situ, cancer Cone biopsy CIN indicates cervical intraepithelial neoplasia. SIL indicates squamous intraepithelial lesion. HSIL+ indicates HSIL, AGC, adenocarcinoma in situ and/or cancer. ASC-US + indicates ASC-US, ASC-H, LSIL and/or HSIL+. DEP indicates diagnostic excisional procedure (e.g., cone biopsy, loop excision). Smoking cessation is advised in all patients. HIV testing should be offered in all women with biopsy-proven CIN 3. Additional information on colposcopy by UCSF authors can be found by typing GLOWM and colposcopy into your search engine. 3- Sawaya & Smith-McCune, August 2010
17 Guidelines for treatment of biopsy-proven cervical intraepithelial neoplasia (CIN) 2 (moderate dysplasia) and CIN 3 (CIS, severe dysplasia), 2010 San Francisco General Hospital CIN 2 and 3 can be treated by either an ablative or an excisional procedure in non-pregnant women. Ablative methods include laser and cryotherapy; excisional methods include loop excision and cone biopsy. In adolescents and young women with satisfactory colposcopy, CIN 2 may be managed with colposcopy and cytology surveillance every 6 months; routine screening may resume after 2 normal cytology tests and colposcopic exams. If surveillance is chosen, CIN 2 may be followed for up to 24 months without treatment. Alternatively, ablative therapy (e.g., cryotherapy) is the preferred treatment. Treatment Factors affecting choice Cryotherapy Laser ablation Loop excision (aka LEEP) Cone biopsy Appropriate for CIN 2 or CIN 3 if following general criteria met: Satisfactory colposcopy No prior cervical treatment Lesion(s) completely visible and <2 cm in diameter Lesion(s) can be covered entirely with the cryoprobe Often used for large lesions (>2 cm) with or without vaginal extension. Candidacy same as for cryotherapy. Choose for CIN 2 or CIN 3 lesions in which cryotherapy is inappropriate (e.g., unsatisfactory colposcopy, endocervical curettage with dysplasia). Choose instead of loop excision if suspicion for malignancy or recurrent atypical glandular cells (AGC) on cytology and/or cervical architecture disrupted. Guidelines for follow-up after treatment of CIN 2 and CIN 3 Treatment Follow-up Cryotherapy or laser ablation Loop excision (LEEP) or cone biopsy Dysplasia in specimen, negative endocervical margin No dysplasia in specimen Dysplasia in specimen, positive endocervical margin Cytology in 6 and 12 months; colposcopy for ASC-US+. After 2 normal tests, annual cytology. Cytology in 6 and 12 months; colposcopy for ASC-US+. After 2 normal tests, annual cytology. Cytology and ECC in 6 months; colposcopy for ASC-US+. Then, cytology alone in 12 months; colposcopy for ASC-US+. Repeat excision if HSIL+ at any time. After 2 normal tests, annual cytology. Hysterectomy Annual cytology. After 3 consecutive, normal tests, screening may be performed every 3 years. ECC indicates endocervical curettage. ASC-US indicates atypical squamous cell of undetermined significance. HSIL indicates high-grade squamous intraepithelial lesion. HSIL+ indicates HSIL, AGC, adenocarcinoma in situ and/or cancer. ASC-US + indicates ASC-US, ASC-H, LSIL and/or HSIL+. Guidelines for treatment and follow-up of adenocarcinoma in situ Treatment Follow-up Hysterectomy (treatment of choice) Cone biopsy Annual cytology. After 3 consecutive, normal tests, screening may be performed every 3 years. Cytology and ECC every 4 months for 2 years, then every 6 months until hysterectomy. Smoking cessation is advised in all patients. HIV testing should be offered in all women with biopsy-proven CIN Sawaya & Smith-McCune, August 2010
Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure
Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationManagement Algorithms for Abnormal Cervical Cytology and Colposcopy
Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More informationDisclosures. Learning objectives. George F. Sawaya, MD. I have nothing to disclose.
Well Woman Visits in 2018: How Should We Approach Cervical Cancer Screening and Routine Pelvic Examinations? George F. Sawaya, MD Disclosures I have nothing to disclose. Professor, Obstetrics, Gynecology
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationManagement of Abnormal Cervical Cytology and Histology
Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline
More informationDysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
More informationHPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series
HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way Prevalence HPV in Young Adults in U.S HPV genotypes 55-60% of All cancers 20%
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationManagament of Abnormal Cervical Cytology and Histology
Managament of Abnormal Cervical Cytology and Histology Ali Ayhan, M.D Başkent University Faculty of Medicine Department of Gynecology and Obstetrics Division of Gynecologic Oncology Abnormal Cytologic
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationSamuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida
Making sense of the new Pap smear screening guidelines. Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida Case 17 year old G1P0010 with first sexual encounter
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationNo Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016
Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI Medical College of Wisconsin May 6,
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationTreatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman?
Treatment of Cervical Intraepithelial Neoplasia Karen Smith-McCune Professor, Department of Obstetrics, Gynecology and Reproductive Sciences I have no conflicts of interest Case How would you manage this
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationCervical Cancer Screening Update. Melissa Hartman, DO Women s Health
Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse
More informationOver-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationCervical Dysplasia and HPV
Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk
More informationManagement that provides continuity of care for women
Management that provides continuity of care for women If women are diagnosed with reproductive tract infection, prompt treatment should be instituted according to the WHO guidelines. Though it may be preferred
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationLauren O Sullivan, D.O. February 19, 2015
Lauren O Sullivan, D.O. February 19, 2015 1. Review basics of Pap smear, cervical dysplasia/cancer and HPV infection. 2. Review 2012 updated screening guidelines. 3. Discuss how and where to find updated
More informationBecoming a colposcopist: Colposcope case studies
Becoming a colposcopist: Colposcope case studies Seon-Kyung Lee, M.D. Department of Obstetrics and Gynecology College of Medicine, Kyung Hee University Value of Colposcopy Cytology is an effective screening
More informationUpdated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D.
Updated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D. 27 May, 2014 London, England Faculty Disclosure X No, nothing to disclose Yes, please specify
More informationCervical Conization. 1
Cervical Conization www.zohrehyousefi.com 1 Cone Biopsy is a surgical procedure with removal of a cone shaped portion of the cervix The extent of involvement of epithelium on the ectocervix has been clearly
More informationCervical Cancer Screening
Cervical Cancer Screening MEGAN CHENEY, MD MPH MEDICAL DIRECTOR, THE WOMEN S CENTER ASSISTANT DIRECTOR, BGSMC OBGYN RESIDENCY PROGRAM SECTION CHIEF, THE WOMEN S HEALTH INSTITUTE Objectives Understand proper
More informationYour Colposcopy Visit
Introduction Welcome to the colposcopy clinic. This booklet tells you about. The colposcopy examination.. Tests that are done in the colposcopy clinic.. What these tests look for Take a few minutes to
More informationChapter 10: Pap Test Results
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
More information9/18/2008. Cervical Cancer Prevention for Adolescent Populations Garcia. Faculty disclosure. Objectives. HPV Positivity by Age (UK)
Faculty disclosure Cervical Cancer Prevention for Francisco, MD, MPH Associate Professor Obstetrics & Gynecology Mexican American Studies Public Health Francisco, MD, MPH has no financial affiliations
More informationPRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT
PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C.
More informationCervical Cancer Screening Guidelines Update
Frontier AIDS Education and Training Center Cervical Cancer Screening Guidelines Update Hillary Liss, MD Harborview Medical Center, Madison and Adult Medicine Clinics Frontier AETC, Medical Program Director
More informationSOGC / SCC Clinical Practice Guideline
SOGC / SCC Clinical Practice Guideline Colposcopic Management of Abnormal Cervical Cancer Screening and Histology These Clinical Practice Guidelines have been prepared and approved by the Executive and
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationConflict of Interest Disclosure. Anita L. Nelson, MD. Principles Underlying Screening Recommendations. Learning Objectives
Advanced Colposcopy Conflict of Interest Disclosure Anita L. Nelson, MD Anita L. Nelson, MD Professor OB-GYN David Geffen School of Medicine at UCLA CFHC s 2014 Women s Health Update Berkeley, CA May 20,
More informationI have no financial interests in any product I will discuss today.
How Should We Approach Cervical Cancer Screening and Routine Pelvic Examinations in 2019? Michael Policar, MD, MPH Professor Emeritus Department of Obstetrics, Gynecology and Reproductive Sciences University
More informationCervical Cancer Prevention in the 21 st Century Changing Paradigms
Cervical Cancer Prevention in the 21 st Century Changing Paradigms Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M.
More information1 Cervical Cancer Prevention and Screening: Update 2010 Michael S. Policar, MD, MPH Clinical Professor of Ob, Gyn, and RS UCSF School of Medicine policarm@obgyn.ucsf.edu No commercial disclosures for this
More informationBRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM
BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM DATE: NOVEMBER 19, 2016 PRESENTER: DR. DIRK VAN NIEKERK 1 Conflict of Interest Disclosure Nothing to disclose 2 ..in the beginning of the malady it
More informationUpdate on Cervical Cancer Screening. Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationUpdate on Cervical Cancer Screening
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationClinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages years
Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages 21-39 years Michelle I. Silver, PhD, ScM Cancer Prevention Fellow National Cancer Institute Division of Cancer
More informationEU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
More information6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention
6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationCervical Skills. Dr Margaret Laing Queen Elizabeth University Hospital
Cervical Skills Dr Margaret Laing Queen Elizabeth University Hospital What is screening? Screening is a test offered to an apparently well person with the possibility of detecting a serious disease before
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationGLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016
GLANDULAR LESIONS PITFALLS IN MANAGEMENT Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016 Introduction Cervical glandular lesions are much less common than squamous lesion Incidence
More informationHKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists
HKCOG Guidelines Guidelines on the Management of An Abnormal Cervical Smear Number 3 revised November 2002 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College of
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHuman Papillomavirus (HPV) and Cervical Cancer Prevention
Human Papillomavirus (HPV) and Cervical Cancer Prevention MOA Autumn Convention November 3, 2017 David J Boes, DO, FACOOG (Dist.) Associate Professor, MSU-COM 1 Disclosures None relative to this presentation
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationHuman Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita
Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationUnderstand Your Results
Understand Your Results The Pap test takes little time and may save your life. This simple screening test checks for cell changes in the cervix, the opening of the uterus. If your Pap results were abnormal,
More informationRunning head: EVIDENCE-BASED MEDICINE TWO-STEP DISCREPANCY
Evidence-Based Medicine Two-Step Discrepancy 1 Running head: EVIDENCE-BASED MEDICINE TWO-STEP DISCREPANCY Evidence-Based Medicine Two-Step Discrepancy Julie Nelson Texas Woman s University Philosophy of
More informationWOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16
WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 05/01/95 ANY MISSING OR INCOMPLETE TEST RESULTS
More informationScottish Cervical Screening Programme. Colposcopy and Programme Management
Scottish Cervical Screening Programme Colposcopy and Programme Management Addendum to NHSCSP Publication No 20 Second Edition Exceptions Applicable in NHS Scotland April 2013 (Final Version 2.8 to incorporate
More informationCERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)
CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) The cervix constitutes the lower third of the uterus. It is in two parts, the endocervix and the ectocervix. Ectocervix is covered with squamous epithelium. Endocervix
More informationLABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 09/5/95 ANY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM.
More informationWOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 0 / 0 / 6 ANY MISSING OR INCOMPLETE TEST RESULTS
More informationX-Treme Primary Care: HPV and STIs. Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers
X-Treme Primary Care: HPV and STIs Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers Learning Objectives Review recommendations for HPV related cancer screening in
More informationLABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 0/0/0 ANY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM.
More informationPerfecting the Prevention of Cervical cancer. I have no financial interests in any product I will discuss today. Preview
Perfecting the Prevention of Cervical cancer Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests in any
More informationPREVENTION OF CERVICAL CANCER
PREVENTION OF CERVICAL CANCER Author: Dr R. Fuentes MBchb, Havana Spec. OB,GY-Havana- 2011 CONTENT TABLE Abbreviations 2 Introduction 4 The natural history of Cervical cancer 4 Risk Factors 4 Incidence
More informationFocus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010
HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,
More informationGuidelines for Breast, Cervical and Colorectal Cancer Screening
Guidelines for Breast, Cervical and Colorectal Cancer Screening Your recommendation counts. Talk to your patients about screening for cancer. CancerCare Manitoba provides organized, population-based screening
More informationProposed new national cervical screening program. Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns
Proposed new national cervical screening program Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns www.drelizabethjackson.com Cervical cancer in Australia 12th most common cancer affecting Australian
More informationCERVICAL CANCER FACTSHEET. What is cervical cancer?
CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationCuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015
Programme Report 2014/2015 Contents Summary points 2 Introduction to the statistics 2014/2015 3 Part 1 Cervical screening activity 3 Programme coverage 4 Laboratory turnaround time 7 Notification of results
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationCryotherapy has No Place in Colposcopy Practice
Cryotherapy has No Place in Colposcopy Practice No financial disclosures No conflicts of interest ? Precision? Personalized Medicine? Best Evidence Based Practice Prinicipals of Surgical Management CIN1
More informationTwenty-first refresher course. Chan Kit Sheung
Twenty-first refresher course Chan Kit Sheung 7-5-2015 Case 1 Case 1, 29y old, G3P2, referred from MCHC Cervical smear on 27-9-2013: LGSIL, defaulted appointment Cervical smear in 12/2014: negative Colposcopy
More informationAn Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program
An Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program Susan Baum, MD, MPH NM Nurse Practitioner Council Annual Conference April 20, 2012 I have no commercial relationships related
More informationPap Reports. Of all women undergoing Papanicolaou (Pap) What Now? Women s Health. What has changed?
Pap Reports What Now? Prafull Ghatage, MB, ChB, FRCSC As presented at the Calgary Health Region s 37th Annual Mackid Symposium: Cancer Care in the Community (May 22, 2003) Of all women undergoing Papanicolaou
More informationLABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 08/5/94 ANY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM.
More informationStreamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014
Streamlining Protocols-From Strategy to Implementation Doreen Ramogola-Masire Botswana UPenn Partnership 18-20 June 2014 Botswana-UPenn Partnership Partnership between Government of Botswana, University
More informationCytology Report Format
Squamous Precursor Lesions and Malignancies In Pap Test Dina R. Mody, MD, FCAP Director of Cytology The Methodist Hospital, Houston, TX Professor of Pathology and Laboratory Medicine Weill Medical College
More informationGUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version
More informationWorkshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical
More informationGoals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-
Your PAP and HPV Update 2015 Connie Mao, MD University of Washington Goals Primary HPV Testing- Is it time to stop doing pap smears? Screening Intervals- Should patients have a choice? HPV Vaccine Updates-
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationPreventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE
Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE DR GARY FENTIMAN, CLINICAL LEADER COLPOSCOPY, N C S P TAKE-HOME LESSONS Vaccination is Primary Prevention for Cervical Cancer Women
More information